In an era of health reform, diagnostic technologies that focus on prevention and test the viability of expensive treatment options are becoming increasingly valuable to health providers, payers, and patients. Historically, investment in this sector has not seen the vigor demonstrated with medical devices or biotech innovations. However, in today’s environment, diagnostics are becoming attractive opportunities for companies looking for collaborations or acquisitions as well as investors looking for cutting-edge technologies, all creating a robust industry on the brink of breaking through to the mainstream.
In this presentation, panelists will:
- Provide insight on the diagnostic industry on a local and national level
- Discuss key elements that are reviewed when assessing start-up opportunities
- Discuss where opportunities exist for maximizing profits
- Provide new strategies for raising funds in this dynamic marketplace
Panelist:
Ronald S. Eppen, Partner, Foley & Lardner LLP
Lucy Lu, Vice President of Business Development, Crescendo Bioscience
Natasha Paul, Ph.D., Scientific Investigator, TriLink Biotechnologies, Inc.
Jon Vance, Director, Avondale Partners, LLC
Related Insights
18 March 2025
Foley Viewpoints
No Action Letter – Regulation D Rule 506(c)
The SEC now permits public marketing of private placements, without burdensome investor wealth verification requirements, if the investment is big enough.
18 March 2025
Energy Current
Mexican Government Proposes Bill to Regulate the Energy Sector
On February 4, 2025, Mexican President Claudia Sheinbaum submitted a bill to the Mexican Senate to revoke, issue, and amend various energy laws in accordance with the constitutional amendments passed in December 2024.
18 March 2025
Innovative Technology Insights
The Symbiotic Future of Quantum Computing and AI
While quantum computers remain in their infancy, AI could provide a bridge to unlocking their potential.